TNF-alpha Antagonists for AECOPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial

Phase 2/3 Completed 81 enrolled Ottawa Hospital Research Institute

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether treatment with antibiotics plus a TNFalpha antagonist will provide more effective treatment for acute COPD exacerbation compared to the current standard treatment of antibiotics plus prednisone.

Timeline

Start: 2008-11
Primary completion: 2011-08
Completion: 2011-10

Publications

Aaron SD, Vandemheen KL, Maltais F, Field SK, Sin DD, Bourbeau J, Marciniuk DD, FitzGerald JM, Nair P, Mallick R. TNFalpha antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. Thorax. 2013 Feb;68(2):142-8. doi: 10.1136/thoraxjnl-2012-202432. Epub 2012 Nov 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Etanercept	Protein / enzyme biologic	50 mg	Subcutaneous
Comparator	Prednisone	Other / unclassified	40 mg	Oral
Background	Levofloxacin	Small molecule	750 mg	Oral

TNF-alpha Antagonists for AECOPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial

Summary

Timeline

Publications

Drugs

Indications